ClinicalTrials.gg
CompletedNCT05456984Updated Dec 13, 2022

The PsychOsis and Diabetes Service Model (PODS) Population Profile Study.

An observational study in Type2Diabetes and Severe Mental Disorder, sponsored by King's College London. Completed at 9 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-13.

Sponsored by King's College London · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
125
Ages
18 Years and older
Sex
All
01

Study summary

People with severe mental illness (SMI), defined as psychotic and bipolar disorders, die 17-20 years earlier than the general population, the most common cause of death being cardiovascular diseases (CVD). The major contributor to CVD mortality in SMI is the increased prevalence of type 2 diabetes (T2D) compared to the general population. T2D is a paradigm of a single condition that progresses to multiple conditions. T2D requires annual reviews of 9 diabetes care processes and for patients to adopt multiple self-care tasks to prevent diabetes complications. The 9 diabetes care processes include: 3-6 monthly blood glucose measurement (HbA1c) with appropriate targets; blood pressure measurements and targets depending on diabetes complication status; annual blood cholesterol measurement; kidney function testing with urinary albumin; kidney function testing with serum creatinine; weight check; smoking status; diabetes annual eye screening; and annual foot examination.

In the National Diabetes Audit 2016-17, people with SMI and T2D were 10% less likely to take up all 9 diabetes care processes and have worse glycaemic control as a result. Therefore the aim of this study is to determine who is receiving these care processes and to develop new care pathways/interventions that support this population.

This project is a cross-sectional study and will take place in Lambeth south London, an area with high prevalence of SMI, and therefore T2D, and deprivation. W aim to profile the entire population of people with SMI and T2D within the Hills Brook and Dales and StockWELL Primary Care Networks. The investigators will access the participants medical records and record details of their latest physical health assessment and ask them to complete 7 validated questionnaires and brief informal interview either face to face in their GP surgery or over the phone. This project has been funded by the Burdett Trust for Nursing.

Read the detailed description

The practice manager at each participating GP practices will run a combined search using read codes for SMI and for type 2 diabetes on the Egton Medical Information System (EMIS) electronic patient record. This will generate a list/register of all the people who potentially meet the study inclusion criteria. Next GPs or practice staff will invite the potentially eligible to participate in the study by sending them a letter and the participant information sheet. The participant will be asked to contact the research team if they would like to participate or have any further questions. If they agree to the study they receive an information sheet and consent form and will have the opportunity to ask the research team about the study.

It is expected that the total of eligible participants will be 578 from HBD and 472 for StockWELL PCN. This is because HBD PCN have a total of 57,863 patients and StockWELL have 47,199. Type 2 diabetes prevalence for Lambeth is around 5% and there are 5253 people with diabetes from the 2 PCNs which means that based on the estimated prevalence of SMI and T2D in primary care of 20%, the total population of potentially eligible participants will be in the region of 1,000. It is anticipated that 20% of people will respond to the study invitation which would mean a total population of around 200 and depending on the time available to recruit participants and the rate at which GP practices join the study and run the searches, the investigators aim to recruit at least 120 within the study period.

This will be a population-based cross-sectional survey of the total population of people with SMI and T2D registered with HBD PCN and StockWELL PCN. The research team will carry out a case note review of identifiable electronic medical records at the clinical site, information that will be selected will include the date of both diagnoses, duration of both diagnoses and medication history after consent has been obtained. This information will be written in a pseudoanonymised case report form with an ID number replacing patient identifiers and will then be kept in a locked filling cabinet in James Clerk Maxwell Building, King's College London.

The research team will ask the participant to complete 7 validated questionnaires (Diabetes Distress Scale, International Physical Activity Scale, Quality of Life Scale, self-report Global Assessment of Functioning, Alcohol Usage Disorders Identification Test, Drug Abuse Screening Test and Empower Up). This will be done either over the phone or in person and the participants GP surgery, depending on their preference.

The GP Practice will be asked to conduct a routine physical health assessment on the participant, if they have not had one in the last 3 months. This would be part of their routine clinical care and consist of HbA1c (mmol/mol); BP (mmHg); eGFR (mL/min); cholesterol (mmol/mol); BMI (m/kg2).

The research worker will then conduct a brief interview, they will rate the severity of psychiatric symptoms using a validated rating scale and they will discuss how the participant accesses support for diabetes self-management, whether they have any experience of digital interventions and their thoughts on them and finally, preferences on where and how, they receive their diabetes support. This will be carried out either over the phone or in person, depending on the participants preference and will take about 30 minutes.

If the participant lacks capacity to consent, they will be asked to consent again in a few weeks to see whether capacity has been restored. If the participant still lacks capacity or they lose capacity during the study, the participant or clinical team will be asked to elect a personal or professional and consultee. The research team will contact them and ask if they are happy to consent on the participants behalf.

02

Conditions studied

  • Type2Diabetes
  • Severe Mental Disorder

Browse trials for

03

In context

Mental Disorders

2,148 studies on the registry are indexed under Mental Disorders; 425 are open to participants now.

This study's enrollment of 125 is below the median of 200 across 488 observational studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

King's College London is the lead sponsor of 519 studies on the registry; 126 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participant will all have type 2 diabetes and a severe mental illness. They will be recruited from two primary care networks (HBD and StockWELL), both of these are situated in Lambeth, London.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants will need to have a diagnosis of type 2 diabetes and bipolar affective disorder or psychosis.
  • Capacity to consent; if participant does not currently have capacity to consent, we will ask them again in a few weeks to see whether capacity has been restored. If the participant still lacks capacity, we will ask the potential participant/their clinical team if there is a professional or a personal nominee to consent on their behalf.
  • Participants must be 18 years or older.

Exclusion criteria

Exclusion Criteria:

  • Adults without an SMI diagnosis.
  • Adults with SMI and other types of diabetes, e.g. type 1 diabetes or gestational diabetes (as different management).
  • Pregnancy.
  • Dementia.
  • Organic psychosis.
  • Moderate-severe learning disabilities
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
125 participants (actual)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Diabetes Distress Scale

    To profile the current psychological and physical status of patients registered in the Hills Brook and Dales PCN and the StockWELL PCN. The Diabetes Distress Scale will be administered.

    Time frame: 1 day

  2. International Physical Activity Questionnaire

    To profile the current psychological and physical status of patients registered in the Hills Brook and Dales PCN and the StockWELL PCN. The International Physical Activity Questionnaire will be administered.

    Time frame: 1 day

  3. Quality of Life Scale

    To profile the current psychological and physical status of patients registered in the Hills Brook and Dales PCN and the StockWELL PCN. The Quality of Life Scale will be administered.

    Time frame: 1 day

  4. Global Assessment of Functioning

    To profile the current psychological and physical status of patients registered in the Hills Brook and Dales PCN and the StockWELL PCN. The Global Assessment of Functioning scale will be administered.

    Time frame: 1 day

  5. Alcohol usage disorder identification test

    To profile the current psychological and physical status of patients registered in the Hills Brook and Dales PCN and the StockWELL PCN. The Alcohol Usage Disorders Identification Test will be administered.

    Time frame: 1 day

  6. Drug abuse screening test

    To profile the current psychological and physical status of patients registered in the Hills Brook and Dales PCN and the StockWELL PCN. The Drug Abuse Screening Test will be administered.

    Time frame: 1 day

  7. Brief psychiatric rating scale

    To profile the current psychological and physical status of patients registered in the Hills Brook and Dales PCN and the StockWELL PCN. The Brief Psychiatric Rating Scale will be administered.

    Time frame: 1 day

  8. Empower up

    To profile the current psychological and physical status of patients registered in the Hills Brook and Dales PCN and the StockWELL PCN. The Empower Up Questionnaire will be administered.

    Time frame: 1 day

Secondary outcomes

  1. Diabetes treatment

    Investigators will use an open interview to find out where and how the participant would like their diabetes treatment.

    Time frame: 1 day

07

Study locations

9 sites
  • Herne Hill Group Practice
    London, SE24 9QP, United Kingdom
  • Knight's Hill
    London, SE27 0DF, United Kingdom
  • Brixton Hill
    London, SW2 1AE, United Kingdom
  • Northwood Group Practice
    London, SW2 3DX, United Kingdom
  • Binfield Road Practice
    London, SW4 6TB, United Kingdom
  • Springfield Medical Centre
    London, SW8 2SH, United Kingdom
  • Beckett House
    London, SW9 9DL, United Kingdom
  • Grantham Practice
    London, SW9 9DL, United Kingdom
  • Stockwell Group Practice
    London, SW9 9TJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Anonymised data can be shared if requested.

Supporting information: Study protocol, Informed consent form

Time frame: Once the study is completed.

Access criteria: Email Kirsty Winkley to request access.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05456984
Collaborators
Burdett Trust for Nursing
Responsible party
Sponsor
First posted
Jul 13, 2022
Start date
May 3, 2022
Primary completion
Aug 10, 2022
Completion
Aug 10, 2022
Last update
Dec 13, 2022

Study contacts

Kirsty Winkley
principal investigator · King's College London University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion